TY  - CONF

T1  - A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line treatment of patients with non-small cell lung cancer (NSCLC) using change in tumor size (CTS).

JO  - Journal of Clinical Oncology

PY  - 2013/05/20

AU  - Talbot DC

AU  - Blackhall FH

AU  - Kowalski D

AU  - Ramlau R

AU  - Belper G

AU  - Grossi F

AU  - Lerchenmuller CA

AU  - Pinder MC

AU  - Mczger J

AU  - Danson S

AU  - Callies S et al

ED  - 

VL  - 31

Y2  - 2024/12/26

ER  -